Conexiant
Login
  • The Analytical Scientist
  • The Cannabis Scientist
  • The Medicine Maker
  • The Ophthalmologist
  • The Pathologist
  • The Traditional Scientist
The Pathologist
  • Explore Pathology

    Explore

    • Latest
    • Insights
    • Case Studies
    • Opinion & Personal Narratives
    • Research & Innovations
    • Product Profiles

    Featured Topics

    • Molecular Pathology
    • Infectious Disease
    • Digital Pathology

    Issues

    • Latest Issue
    • Archive
  • Subspecialties
    • Oncology
    • Histology
    • Cytology
    • Hematology
    • Endocrinology
    • Neurology
    • Microbiology & Immunology
    • Forensics
    • Pathologists' Assistants
  • Training & Education

    Career Development

    • Professional Development
    • Career Pathways
    • Workforce Trends

    Educational Resources

    • Guidelines & Recommendations
    • App Notes

    Events

    • Webinars
    • Live Events
  • Events
    • Live Events
    • Webinars
  • Profiles & Community

    People & Profiles

    • Power List
    • Voices in the Community
    • Authors & Contributors
  • Multimedia
    • Video
    • Podcasts
Subscribe
Subscribe

False

The Pathologist / Issues / 2023 / Jan / Proteomic Prognosis
Oncology Omics Oncology Genetics and epigenetics Molecular Pathology

Proteomic Prognosis

How proteins, RNA, and smoking status can predict lung cancer outcomes

By George Francis Lee 01/26/2023 News 1 min read

Share

Lung cancer remains the leading cause of death in cancer patients worldwide (1). Could advanced analytical investigations change the status quo? A recent study subjected 87 lung adenocarcinoma (LUAD) tumors to a plethora of techniques, including whole-genome sequencing, transcriptome sequencing, mass spectrometry-led proteomics and phosphoproteomics, and reverse-phase protein arrays (2). The multi-pronged approach led to the discovery of three distinct forms of LUAD – a transition-high subtype linked to non-smokers, a transversion-high subtype linked with current smokers, and a structurally altered subtype linked to former smokers and characterized by TP53 alterations and genome-wide structural alterations. 

The researchers also identified that protein expression and groups of RNA within sample tumors were linked to cell immunity and concentration of cancer cells within tissue. The team was then able to identify and validate the expression signatures of RNA and proteins and establish their association with patient survival.

When the tumor subtypes were compared by outcome, the team saw that expression and histological subtypes were strongly associated with metastasis-free survival (MFS). Meanwhile, somatic genome signature subtypes were not linked with overall or MFS. The paper suggests that the biological factors of LUAD recorded in the proteomic approach hold a determining effect on MFS.

Finally, the authors of the paper highlighted how a detailed understanding of th e different molecular subtypes of LUAD could lead to therapy pathways designed to halt the development in pre-cancerous and early-stage LUAD tumors.

Newsletters

Receive the latest pathology news, personalities, education, and career development – weekly to your inbox.

Newsletter Signup Image

References

    1. American Cancer Society (2023). Available at: http://bit.ly/3QMt8Kj.
    2. AR Soltis et al., Cell Rep, 3, 100819 (2022) PMID: 36384096.

About the Author(s)

George Francis Lee

Interested in how disease interacts with our world. Writing stories covering subjects like politics, society, and climate change.

More Articles by George Francis Lee

Explore More in Pathology

Dive deeper into the world of pathology. Explore the latest articles, case studies, expert insights, and groundbreaking research.

False

Advertisement

Recommended

False

Related Content

Turning Tides
Omics
Turning Tides

January 9, 2024

3 min read

A new study shows evidence for sustained human-to-human transmission of mpox since 2016

“Pop” Goes the Sensor
Omics
“Pop” Goes the Sensor

January 19, 2022

1 min read

A new device could help scientists identify signs of arrhythmia, heart attack, and cardiac fibrosis

Improving Risk Stratification
Omics
Improving Risk Stratification

February 3, 2022

1 min read

Two genes have been identified that may be linked to prostate cancer outcomes

The Ultimate Vision for Rare Disease
Omics
The Ultimate Vision for Rare Disease

February 28, 2022

1 min read

Genomics and computational pathology can take rare disease diagnostics to the next level

False

The Pathologist
Subscribe

About

  • About Us
  • Work at Conexiant Europe
  • Terms and Conditions
  • Privacy Policy
  • Advertise With Us
  • Contact Us

Copyright © 2025 Texere Publishing Limited (trading as Conexiant), with registered number 08113419 whose registered office is at Booths No. 1, Booths Park, Chelford Road, Knutsford, England, WA16 8GS.